News

Total revenue for the fourth quarter of 2008 increased to $31.2 million, compared with $19.3 million in the fourth quarter of 2007. Product revenue from the Oncotype DX(R)

Fiscal 2009 first quarter highlights Gross profit grew 5% to $15.3 million on increased sales and continued operating leverage. Effective tax rate declined to 33.6% due primarily to

During the first nine months of the fiscal year ending March 31, 2009 (April 1 to December 31, 2008), the Japanese economy experienced a further deceleration in its

The SonoDrugs collaboration aims to develop new materials and drug nanocarrier systems for improved localized drug delivery that can be activated by ultrasound waves. Magnetic resonance imaging (MRI)

Nuvo is in the process of finalizing its resubmission for Pennsaid approval, which it expects to file with the FDA within the next 60 days. Upon acceptance of

The Beneficial study, which was a Phase II double-blind, placebo-controlled, randomized trial of alagebrium in patients with chronic systolic heart failure; the Break study, which was a Phase

Under the terms of the merger transaction, Nuvelo issued approximately 4.87 million new shares of common stock to shareholders of pre-merger Arca. As a result, former Arca pre-merger

According to the company, the Taxus Liberte is the only second-generation drug-eluting stent approved for use in Japan. Design improvements over the company’s first-generation Taxus Express2 stent include

Cannasat has received a no objection letter from Health Canada to conduct this clinical study for this product that is designed to help manage neuropathic pain and other